Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischmann

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
International Journal of Geriatric Psychiatry|January 13, 2004
Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID)Frans R Verhey, Peter Houx, Natascha Van Lang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 19, 2016
Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus ErythematosusJohn R Doedens, Wendell D Jones, Kay Hill, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 18, 2019
A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With SynovitisRoy M Fleischmann, Henning Bliddal, Francisco J Blanco, et al.
Public Health Reports (Washington, D.C. : 1974)|April 2, 2024
Wastewater Surveillance of US Coast Guard Installations and Seagoing Military Vessels to Mitigate the Risk of COVID-19 Outbreaks, March 2021-August 2022Gregory J Hall, Eric J Page, Min Rhee, et al.
Annals of the Rheumatic Diseases|September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
Annals of Internal Medicine|March 13, 1999
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialL W Moreland, M H Schiff, S W Baumgartner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2017
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10Alexandra Zanin-Zhorov, Jonathan M Weiss, Alissa Trzeciak, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
International Journal of Geriatric Psychiatry|January 13, 2004
Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID)Frans R Verhey, Peter Houx, Natascha Van Lang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 19, 2016
Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus ErythematosusJohn R Doedens, Wendell D Jones, Kay Hill, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 18, 2019
A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With SynovitisRoy M Fleischmann, Henning Bliddal, Francisco J Blanco, et al.
Public Health Reports (Washington, D.C. : 1974)|April 2, 2024
Wastewater Surveillance of US Coast Guard Installations and Seagoing Military Vessels to Mitigate the Risk of COVID-19 Outbreaks, March 2021-August 2022Gregory J Hall, Eric J Page, Min Rhee, et al.
Annals of the Rheumatic Diseases|September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
Annals of Internal Medicine|March 13, 1999
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialL W Moreland, M H Schiff, S W Baumgartner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2017
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10Alexandra Zanin-Zhorov, Jonathan M Weiss, Alissa Trzeciak, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Pageof 16